Professor John R Petrie
Image: Professor John R Petrie
University of Glasgow, Glasgow
John Petrie (@johnrpetrie) has a long-term interest in diabetes control and complications. He was Chief Investigator of the international JDRF-funded REMOVAL trial, the longest and largest trial of metformin in type 1 diabetes to date, and the only one to focus on atherosclerotic cardiovascular disease. John is currently Chair of the Diabetes UK Clinical Study Group (CSG6) on Microvascular and Macrovascular Complications. He is past President of the European Group for the study of Insulin Resistance (2010-2015), a former Associate Editor of Diabetologia, and a current member of the EASD/ADA Technology Committee. He led the early development of the successful Scottish Diabetes Research Network (SDRN, 2005-2010) and chaired the 2017 Scottish “SIGN 154” guideline on glucose-lowering therapy in type 2 diabetes. He was a member of the LEADER trial Global Expert Panel. He Chair of Board of Trustees of the Novo Nordisk UK Research Foundation (registered charity 1056410) and is active on research funding panels including the UK MRC/NIHR EME programme as well as JDRF, NHMRC Australia, and the Danish Diabetes Academy International Committee for Talent Development. John is currently co-PI (with Dr Paresh Dandona, State University of New York) of a JDRF-funded trial of combined adjunct therapy in type 1 diabetes (“TTT1”). He does weekly diabetes clinics (types 1 and 2) at Stobhill Ambulatory Care Hospital, North Glasgow and has responsibility for acute and ongoing care of medical inpatients at Glasgow Royal Infirmary.
